ArticleJournal of nanobiotechnology2022
Inflammation-sensing catalase-mimicking nanozymes alleviate acute kidney injury via reversing local oxidative stress.
Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 56 citations in OpenAlex.
- Advances and perspectives of functional nanomaterials in scavenging reactive oxygen species for acute kidney injury.Bioactive materials · 2026Review
- Advanced nanocatalytic medicine for genitourinary diseases: Reactive oxygen modulation, precision therapeutics, and clinical translation.Materials today. Bio · 2026Article
- Size-dependent ruthenium/ceria nanozymes synchronize catalytic ROS scavenging and electrostatic mtDNA sequestration for periodontitis therapy.Journal of nanobiotechnology · 2026Article
- ROS-responsive nanocarriers for the delivery of atorvastatin in ischemic MCAO rats promoting neuroprotection.Materials today. Bio · 2026Article
- Recent advances in stimuli-responsive nanomaterials for the treatment of acute kidney injury.Journal of nanobiotechnology · 2026Review
- Multiscale molecular modeling-directed ROS-responsive nanotherapy for dual-axis regulation of fibrotic and inflammatory signaling in alport nephropathy.Journal of nanobiotechnology · 2026Article
- Research progress of nanoparticles in the diagnosis and treatment of renal ischemia-reperfusion injury.Journal of nanobiotechnology · 2026Review
- Precision Nanomedicine for Renal Tubular Injury: From Passive Accumulation to Subcellular Targeting.International journal of nanomedicine · 2026Review
- Natural Product-Based Nanomicelles: Properties, Fabrication Strategies, and Therapeutic Applications in Diseases.International journal of nanomedicine · 2026Review
- Microplastics in human body: accumulation, natural clearance, and biomedical detoxification strategies.Biomedical engineering letters · 2025Review
- Targeted co-delivery of IL-10 and catalase for cooperative therapeutic effect on acute kidney injury.Bioactive materials · 2025Article
- The Clinical Utility and Plausibility of Oxidative and Antioxidant Variables in Chronic and End-Stage Kidney Disease: A Review of the Literature.International journal of molecular sciences · 2025Review
- Nanozyme-based visual diagnosis and therapeutics for myocardial infarction: The application and strategy.Journal of advanced research · 2025Review
- Nanozymes for Treating Ocular Diseases.Advanced healthcare materials · 2025Review
- Macrophage targeting precision nanomedicine utilizing ROS-responsive metallozyme-loaded nanomicelle for enhanced treatment of gout-induced inflammation.Science and technology of advanced materials · 2025Article
- Periodontal disease and chronic kidney disease: mechanistic insights and novel therapeutic perspectives.Frontiers in cellular and infection microbiology · 2025Review
- Mesoporous MOFs with ROS scavenging capacity for the alleviation of inflammation through inhibiting stimulator of interferon genes to promote diabetic wound healing.Journal of nanobiotechnology · 2024Article
- Review
- Bibliometric and visual analysis of immunisation associated with acute kidney injury from 2003 to 2023.Frontiers in pharmacology · 2024Article
- Engineered nanodrug targeting oxidative stress for treatment of acute kidney injury.Exploration (Beijing, China) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe reactive oxygen species (ROS) and inflammation, a critical contributor to tissue damage, is well-known to be associated with various disease. The kidney is susceptible to hypoxia and vulnerable to ROS. Thus, the vicious cycle between oxidative stress and renal hypoxia critically contributes to the progression of chronic kidney disease and finally, end-stage renal disease. Thus, delivering therapeutic agents to the ROS-rich inflammation site and releasing the therapeutic agents is a feasible solution.
resultsWe developed a longer-circulating, inflammation-sensing, ROS-scavenging versatile nanoplatform by stably loading catalase-mimicking 1-dodecanethiol stabilized Mn
conclusionsThe findings of our study demonstrated the successful attenuation of inflammation and apoptosis in the IRI mice kidneys, suggesting that PTC-M nanozyme could possess promising potential in AKI therapy. This study paves the way for high-performance ROS depletion in treating various inflammation-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.